FDA reminds investors that re-evaluations don’t equal new conclusions. Just ask Capricor and Replimune

FDA scientists question Capricor data; Legend CEO steps down

Capricor's Duchenne cell therapy faces July 29 FDA advisory vote after Phase 3 data integrity criticism; shares crashed two-thirds. Regulatory caution on gene therapy validation signals elevated biotech pipeline and M&A risk.